Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 19/20 | 0.77 |
| ▸ | JAK2 | O60674 | 2/20 | 0.77 |
| ▸ | EGFR | P00533 | 2/20 | 0.77 |
| ▸ | LCK | P06239 | 2/20 | 0.77 |
| ▸ | LYN | P07948 | 2/20 | 0.77 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.77 |
| ▸ | JAK1 | P23458 | 2/20 | 0.49 |
| ▸ | JAK3 | P52333 | 2/20 | 0.49 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.48 |
| ▸ | CDC7 | O00311 | 1/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.48 |
| ▸ | PLK4 | O00444 | 1/20 | 0.48 |
| ▸ | STK25 | O00506 | 1/20 | 0.48 |
| ▸ | CIT | O14578 | 1/20 | 0.48 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.48 |
| ▸ | IKBKB | O14920 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | GAK | O14976 | 1/20 | 0.48 |
| ▸ | CHUK | O15111 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1198317 | 0.92 | SYK (0.77) | SYKJAK2EGFRLCKLYN | |
| R-343 SCHEMBL31060361 | 0.87 | SYK (1.00) | SYKJAK2EGFRLCKLYN | |
| R-343 SCHEMBL2037260 | 0.87 | SYK (1.00) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL2102264 | 0.84 | SYK (0.62) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL1384343 | 0.83 | SYK (0.61) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL31294087 | 0.82 | SYK (1.00) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL2101538 | 0.81 | SYK (0.69) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL12872816 | 0.81 | SYK (0.88) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL2104443 | 0.80 | SYK (0.64) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL3837515 | 0.79 | SYK (1.00) | SYKJAK2EGFRLCKLYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080260754-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | claimed |
| WO-2008118823-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2008-10-02 | — | — | WO | claimed |
| US-8299087-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20110027856-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| US-7834024-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-20080260754-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
| WO-2008118823-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080260754-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | SYK 62/4885JAK2 2/4885EGFR 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.